DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's Laboratories has published its audited standalone and consolidated financial results for Q4 FY2026 and the full year ended March 31, 2026. The Board of Directors approved these results at a meeting on May 12, 2026. The results were published as newspaper advertisements in Business Standard and Andhra Prabha on May 13, 2026, in compliance with SEBI listing regulations. The filing references detailed financial tables including standalone and consolidated revenue figures, segment performance (including formulations, generics, and API segments), and EBITDA metrics. The company held an audit committee meeting prior to Board approval. Key financial highlights include revenue growth across segments and strong performance in both domestic and international markets. The company operates across NSE (DRREDDY), BSE (500124), and NYSE (RDY).
Routine regulatory filing confirming Q4 and FY2026 results publication. Actual stock impact will depend on the underlying numbers in the financial statements — investors should review the full results for revenue, profit, and EPS comparisons against estimates.